Korean J Hematol.  2006 Mar;41(1):1-7. 10.5045/kjh.2006.41.1.1.

Overexpression of the Fanconi Anemia A Gene in Hela and MCF10A Cells

• Park WH

• KMID: 2252321
• DOI: http://doi.org/10.5045/kjh.2006.41.1.1

Abstract

BACKGROUND: Fanconi Anemia (FA) is an autosomal recessive inherited disease, which is characterized by developmental abnormalities, progressive bone marrow failure and a predisposition to cancer. The phenotypes of FA cells show extreme sensitivities towards oxygen and DNA cross linking agents, such as diepoxybutane and mitomycin C (MMC).
METHODS
In the current study, retroviruses expressing the FANCA gene were prepared to create the stable cell lines, Hela (cervical carcinoma) and MCF10A (breast). The expression of FANCA protein in the Hela and MCF10A stable cells, following puromycin selection, was checked using Western blot. The difference in the cell growth between the parent and FANCA expressing cells following MMC treatment was checked using the MTT assay.
RESULTS
The expression of exogenous FANCA protein in the Hela and MCF10A stable cells was observed using Western blot. The MCF10A cells expressing exogenous FANCA were resistant to MMC concentrations with the range 0.01~1 micrometer compared with the MCF10 parent cells. However, at an MMC concentration of 10 micrometer, there was no difference in the susceptibility between the parent and FANCA expressing MCF10 cells. The Hela cells expressing FANCA showed no resistance at any MMC concentration (0.01~10 micrometer).
CONCLUSION
FANCA protein is an important factor for resistance to the cross linking agent, MMC, in MCF10A breast cells, but not in Hela cervical carcinoma cells.

Keyword

Fanconi anemia; FANCA; Hela cell; MCF10A cell

MeSH Terms

Blotting, Western
Bone Marrow
Breast
Cell Line
DNA
Fanconi Anemia Complementation Group A Protein
Fanconi Anemia*
Genes, vif*
HeLa Cells
Humans
Mitomycin
Oxygen
Parents
Phenotype
Puromycin
Retroviridae
DNA
Fanconi Anemia Complementation Group A Protein
Mitomycin
Oxygen
Puromycin

Figure

• 

  Fig. 1 FANCA expression in the stable cell lines. Western blot of the FANCA with antibodies specific for amino acids 1-232 of FANCA is shown. (A) The recombinant expression of zz-FANCA protein in 293T cells by transfection. (B) The recombinant expression of zz-FANCA protein in MCF10A breast cell and Hela cervical carcinoma cells. The mock stable cells (lanes 2 and 4) do not express the FANCA protein.

• 

  Fig. 2 (A) Effect of mitomycin C on the growth of normal Hela cells and FANCA stable Hela cells in vitro. (B) Effect of mitomycin C on the growth inhibition of normal MCF10A cells and FANCA stable MCF10A cells in vitro. Exponentially growing cells were treated with the indicated concentration of mitomycin C for 24, 48 and 72 h. Cell growth inhibition was assessed by MTT assay as described in "Materials and Methods". Results represent the mean of at least four independent experiments. bars, SE.

Reference

1). Bagby GC Jr. Genetic basis of Fanconi anemia. Curr Opin Hematol. 2003. 10:68–76.

2). Joenje H., Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001. 2:446–57.

3). D'Andrea AD., Grompe M. The Fanconi anaemia/BR-CA pathway. Nat Rev Cancer. 2003. 3:23–34.

4). Kwee ML., Poll EH., van de Kamp JJ., de Koning H., Eriksson AW., Joenje H. Unusual response to bifunctional alkylating agents in a case of Fanconi anaemia. Hum Genet. 1983. 64:384–7.

5). Joenje H., Oostra AB., Wijker M, et al. Evidence for at least eight Fanconi anemia genes. Am J Hum Genet. 1997. 61:940–4.

6). Meetei AR., de Winter JP., Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet. 2003. 35:165–70.

7). Meetei AR., Levitus M., Xue Y, et al. X-linked inhe ritance of Fanconi anemia complementation group B. Nat Genet. 2004. 36:1219–24.

8). Medhurst AL., Huber PA., Waisfisz Q., de Winter JP., Mathew CG. Direct interactions of the five known Fanconi anaemia proteins suggest a common functional pathway. Hum Mol Genet. 2001. 10:423–4.

9). Garcia-Higuera I., Taniguchi T., Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001. 7:249–62.

10). Moynahan ME., Pierce AJ., Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001. 7:263–72.

11). Moynahan ME., Chiu JW., Koller BH., Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell. 1999. 4:511–8.

12). Lundberg R., Mavinakere M., Campbell C. Deficient DNA end joining activity in extracts from fanconi anemia fibroblasts. J Biol Chem. 2001. 276:9543–9.

13). Donahue SL., Campbell C. A DNA double strand break repair defect in Fanconi anemia fibroblasts. J Biol Chem. 2002. 277:46243–7.

14). Donahue SL., Campbell C. A Rad50-dependent pathway of DNA repair is deficient in Fanconi anemia fibroblasts. Nucleic Acids Res. 2004. 32:3248–57.

15). Pfeiffer P., Goedecke W., Kuhfittig-Kulle S., Obe G. Pathways of DNA double-strand break repair and their impact on the prevention and formation of chromosomal aberrations. Cytogenet Genome Res. 2004. 104:7–13.

16). van den Bosch M., Lohman PH., Pastink A. DNA double-strand break repair by homologous recombination. Biol Chem. 2002. 383:873–92.

17). Folias A., Matkovic M., Bruun D, et al. BRCA1 interacts directly with the Fanconi anemia protein FAN-CA. Hum Mol Genet. 2002. 11:2591–7.

18). Howlett NG., Taniguchi T., Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002. 297:606–9.

19). Hirsch B., Shimamura A., Moreau L, et al. Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. Blood. 2004. 103:2554–9.

20). West SC. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol. 2003. 4:435–45.